Skip to main content
Addgene

pCN-EGD2-GFP
(Plasmid #45318)

Ordering

This material is available to academics and nonprofits only.
Item Catalog # Description Quantity Price (USD)
Plasmid 45318 Standard format: Plasmid sent in bacteria as agar stab 1 $85

Backbone

  • Vector backbone
    pBM16
  • Total vector size (bp) 6043
  • Modifications to backbone
    SacI/Acc65I digest used to move EGD2pr-GFP-terminator fragment from pCU-EGD2-GFP to the pBM16 backbone.
  • Vector type
    C. glabrata expression
  • Selectable markers
    nourseothricin (NAT)

Growth in Bacteria

  • Bacterial Resistance(s)
    Ampicillin, 100 μg/mL
  • Growth Temperature
    37°C
  • Growth Strain(s)
    DH10B
  • Copy number
    High Copy

Gene/Insert

  • Gene/Insert name
    yeGFP
  • Alt name
    GFP
  • Species
    Synthetic
  • Insert Size (bp)
    717
  • Promoter EGD2

Cloning Information

  • Cloning method Restriction Enzyme
  • 5′ cloning site EcoRI (not destroyed)
  • 3′ cloning site SalI (not destroyed)
  • 5′ sequencing primer M13F
  • (Common Sequencing Primers)

Terms and Licenses

  • Academic/Nonprofit Terms
  • Industry Terms
    • Not Available to Industry
Trademarks:
  • Zeocin® is an InvivoGen trademark.

Depositor Comments

Please note that Addgene's sequencing results found a single nucleotide insertion between bp# 427 and 428 when compared to the full plasmid sequence. According to the depositing laboratory, this insertion has no effect on the function of the plasmid.

How to cite this plasmid ( Back to top)

These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.

  • For your Materials & Methods section:

    pCN-EGD2-GFP was a gift from Brendan Cormack (Addgene plasmid # 45318 ; http://n2t.net/addgene:45318 ; RRID:Addgene_45318)
  • For your References section:

    Expression plasmids for use in Candida glabrata. Zordan RE, Ren Y, Pan SJ, Rotondo G, De Las Penas A, Iluore J, Cormack BP. G3 (Bethesda). 2013 Oct 3;3(10):1675-86. doi: 10.1534/g3.113.006908. 10.1534/g3.113.006908 PubMed 23934995